Tested Applications
| Positive WB detected in | A375 cells |
| Positive IHC detected in | human breast cancer tissue, human brain tissue, human gliomas tissue, human liver cancer tissue, human ovary tumor tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 3 publications below |
| WB | See 7 publications below |
| IHC | See 4 publications below |
| IF | See 5 publications below |
| IP | See 1 publications below |
Product Information
11059-1-AP targets IL-13RA2 in WB, IHC, IF, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | IL-13RA2 fusion protein Ag1534 Predict reactive species |
| Full Name | interleukin 13 receptor, alpha 2 |
| Calculated Molecular Weight | 380 aa, 44 kDa |
| Observed Molecular Weight | 55-70 kDa |
| GenBank Accession Number | BC020739 |
| Gene Symbol | IL13RA2 |
| Gene ID (NCBI) | 3598 |
| RRID | AB_2124417 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q14627 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
IL13RA2, also named as IL13R and CD213a2, belongs to the type I cytokine receptor family. It binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4). IL13RA2 lacks the cytoplasmic domain for signaling, indicating that it acts as a decoy receptor. IL13RA2 gene polymorphisms have been associated with systemic sclerosis (PMID: 16981293). Overexpression of IL13RA2 gene has been reported in several types of cancer, including melanoma, lung cancer, and brain tumor, which makes it a potential immunotherapeutic target (PMID: 19895199; 24970476; 24021875).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for IL-13RA2 antibody 11059-1-AP | Download protocol |
| IHC protocol for IL-13RA2 antibody 11059-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Neuro Oncol Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | ||
J Control Release In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. | ||
Cancer Biol Med IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation.
| ||
Front Pharmacol Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-κB Signaling Pathway. | ||
Front Physiol Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE-/- Mice.
|
